Biogen hopes for breakthrough at Danish Medicines Council after new price drop: "We have taken significant action"
In a video meeting on May 13, the Danish Medicines Council will discuss whether the use of drug Spinraza should be extended to a wider group of patients, after its creator Biogen has lowered the price significantly and new data has emerged.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY CATHERINE BRETT
The Danish Medicines Council, which decides whether new medicines should be accepted for widespread use at Danish hospitals, will decide whether to expand the use of Spinraza (nusinersen) to more patients at a video meeting on May 13, the council reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
